Despite the fact that neither of these drugs represent new pharmacological principles, the development process of these therapies has nonetheless fueled the current evidence-base of COPD by providing an abundance of data from large, well-controlled clinical trials. These data, in result, will undoubtedly impact on the COPD treatment approach, as reflected in global or regional guidelines and strategy for exacerbation prevention in subpopulations only, while usage is associated with risk of sideeffects (pneumonia) [6] , and the contribution of the ICS component to the clinical utility in ICS/ LABA combinations is not always clear to define [7] . With the advent of novel once-daily ICS/ LABA and LABA/LAMA combinations and the availability of a growing body of data, this controversy will rather aggravate than rest in the near future.
For now, what can we learn already from published trials with these novel combinations? allowed to draw some conclusion on the clinical utility of the novel fixed combination.
With regard to symptoms, the LABA/LAMA combination was superior to both LAMA monotherapy [13] and ICS/LABA [14] but not necessarily-this should be supported by benefits on other outcomes. If on the other hand, one followed a step-up approach, it would be necessary to identify those patients gaining more benefit from dual versus single bronchodilation or an ICS/LABA combination.
In fact, some of these information can already be derived from published studies. However, as variability of COPD categorization exists over time, particularly between B and C (with the former also having substantial mortality risk [18] ), this would support introducing dual LABA/LAMA combinations into COPD treatment rather early on than stepping-up.
In any case, current data available so far do not clarify the comparative role of LABA/LAMA versus ICS/LABA as optimal strategy of exacerbation prevention. Currently, both LAMA monotherapy and ICS/LABA combinations are recommended first choice for exacerbating patients, but the SPARK study has shown that a dual LABA/LAMA combination may be more beneficial than one ''gold standard'', LAMA alone. While this appears encouraging for supporters of an ''optimizing bronchodilation first'' approach, it must be noted that in this study, many subjects had a background treatment of ICS, so the 
